Direct Angiotensin II Type 2 Receptor Stimulation Ameliorates Insulin Resistance in Type 2 Diabetes Mice with PPARγ Activation

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Ohshima, Kousei ^a   Mogi, Masaki ^a   Jing, Fei ^a   Iwanami, Jun ^a   Tsukuda, Kana ^a   Min, Li Juan ^a   Ogimoto, Akiyoshi ^a   Dahlöf, Björn ^b   Steckelings, Ulrike M ^c   Unger, Tomas ^d   Higaki, Jitsuo ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADIPONECTIN; ANGIOTENSIN 2 RECEPTOR; COMPOUND 21; DEOXYGLUCOSE; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CELL DAMAGE; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA BINDING; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PHARMACOLOGICAL STIMULATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT OUTCOME; WHITE ADIPOSE TISSUE;

ADIPONECTIN; ADIPOSE TISSUE; ANILIDES; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MALE; MICE; PANCREAS; PPAR GAMMA; RECEPTOR, ANGIOTENSIN, TYPE 2; SULFONAMIDES; THIOPHENES; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 84869137622     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048387     Document Type: Article

References (50)

1. Olivares-Reyes JA, Arellano-Plancarte A, Castillo-Hernandez JR, (2009) Angiotensin II and the development of insulin resistance: Implications for diabetes. Mol Cell Endocrinol 302: 128-139.
2. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003.
3. Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, et al. (2004) Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43: 1003-1010.
4. Olsen MH, Fossum E, Høieggen A, Wachtell K, Hjerkinn E, et al. (2005) Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 23: 891-898.
5. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, et al. (2006) Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: The VALUE trial. J Hypertens 24: 1405-1412.
6. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559.
7. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T, (2000) International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415-472.
8. Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, et al. (2005) Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 54: 991-999.
9. Mitsuishi M, Miyashita K, Muraki A, Itoh H, (2009) Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control. Diabetes 58: 710-717.
10. Abadir PM, Foster DB, Crow M, Cooke CA, Rucker JJ, et al. (2011) Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci U S A 108: 14849-14854.
11. Wu X, Wan Y, Mahalingam AK, Murugaiah AM, Plouffe B, et al. (2006) Selective angiotensin II AT2 receptor agonists: Arylbenzylimidazole structure-activity relationships. J Med Chem 49: 7160-7168.
12. Unger T, Dahlof B, (2010) Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): Implications for AT2 receptor research and therapeutic potential. J Renin Angiotensin Aldosterone Syst 11: 75-77.
13. Iwai M, Tomono Y, Inaba S, Kanno H, Senba I, et al. (2009) AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice. Am J Hypertens 22: 784-791.
14. Darimont C, Vassaux G, Ailhaud G, Negrel R, (1994) Differentiation of preadipose cells: Paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology 135: 2030-2036.
15. Saint-Marc P, Kozak LP, Ailhaud G, Darimont C, Negrel R, (2001) Angiotensin II as a trophic factor of white adipose tissue: Stimulation of adipose cell formation. Endocrinology 142: 487-492.
16. Yvan-Charvet L, Massiera F, Lamande N, Ailhaud G, Teboul M, et al. (2009) Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology 150: 1421-1428.
17. Lehrke M, Lazar MA, (2005) The many faces of PPARgamma. Cell 123: 993-999.
18. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE study (prospective pioglitazone clinical trial in macrovascular events): A randomised controlled trial. Lancet 366: 1279-1289.
19. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 368: 1096-1105.
20. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443.
21. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, et al. (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The periscope randomized controlled trial. JAMA 299: 1561-1573.
22. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, et al. (2000) Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 102: 1834-1839.
23. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, et al. (2001) Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142: 3125-3134.
24. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, et al. (2002) Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 11: 21-30.
25. Takeda K, Ichiki T, Tokunou T, Iino N, Takeshita A, (2001) 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J Biol Chem 276: 48950-48955.
26. Zhao Y, Foryst-Ludwig A, Bruemmer D, Culman J, Bader M, et al. (2005) Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation. J Neurochem 94: 1395-1401.
27. Krege JH, Hodgin JB, Hagaman JR, Smithies O, (1995) A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25: 1111-1115.
28. Ohshima K, Mogi M, Jing F, Iwanami J, Tsukuda K, et al. (2012) Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance. Hypertension 59: 493-499.
29. Tomono Y, Iwai M, Inaba S, Mogi M, Horiuchi M, (2008) Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens 21: 206-212.
30. Mathews ST, Rakhade S, Zhou X, Parker GC, Coscina DV, et al. (2006) Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun 350: 437-443.
31. Shiuchi T, Nakagami H, Iwai M, Takeda Y, Cui T, et al. (2001) Involvement of bradykinin and nitric oxide in leptin-mediated glucose uptake in skeletal muscle. Endocrinology 142: 608-612.
32. Sudo M, Minokoshi Y, Shimazu T, (1991) Ventromedial hypothalamic stimulation enhances peripheral glucose uptake in anesthetized rats. Am J Physiol 261: E298-303.
33. Macari D, Bottari S, Whitebread S, De Gasparo M, Levens N, (1993) Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112b and PD 123319 in the sodium-depleted rat. Eur J Pharmacol 249: 85-93.
34. Widdop RE, Jones ES, Hannan RE, Gaspari TA, (2003) Angiotensin AT2 receptors: Cardiovascular hope or hype? Br J Pharmacol 140: 809-824.
35. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, et al. (2004) Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 47: 5995-6008.
36. Steckelings UM, Widdop RE, Paulis L, Unger T, (2010) The angiotensin AT2 receptor in left ventricular hypertrophy. J Hypertens 28 (Suppl 1):: S50-55.
37. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, et al. (2008) Angiotensin IIs type 2 receptor stimulation: A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118: 2523-2532.
38. Shoelson SE, Lee J, Goldfine AB, (2006) Inflammation and insulin resistance. J Clin Invest 116: 1793-1801.
39. Ouchi N, Parker JL, Lugus JJ, Walsh K, (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11: 85-97.
40. Cawthorn WP, Heyd F, Hegyi K, Sethi JK, (2007) Tumour necrosis factor-alpha inhibits adipogenesis via a beta-catenin/TCF4(TCF7l2)-dependent pathway. Cell Death Differ 14: 1361-1373.
41. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, et al. (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271: 665-668.
42. Miles PD, Barak Y, He W, Evans RM, Olefsky JM, (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 105: 287-292.
43. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, et al. (2002) A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16: 2628-2644.
44. Leung PS, (2007) The physiology of a local renin-angiotensin system in the pancreas. J Physiol 580: 31-37.
45. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, et al. (2004) Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 53: 989-997.
46. Chu KY, Lau T, Carlsson PO, Leung PS, (2006) Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55: 367-374.
47. Cole BK, Keller SR, Wu R, Carter JD, Nadler JL, et al. (2010) Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 55: 715-721.
48. Stephens LA, Thomas HE, Ming L, Grell M, Darwiche R, et al. (1999) Tumor necrosis factor-alpha-activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic beta cells. Endocrinology 140: 3219-3227.
49. Tsiotra PC, Tsigos C, Raptis SA, (2001) TNFalpha and leptin inhibit basal and glucose-stimulated insulin secretion and gene transcription in the HIT-T15 pancreatic cells. Int J Obes Relat Metab Disord 25: 1018-1026.
50. Gupta D, Kono T, Evans-Molina C, (2010) The role of peroxisome proliferator-activated receptor gamma in pancreatic beta cell function and survival: Therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab 12: 1036-1047.